- Latest available (Revised)
- Point in Time (20/03/2005)
- Original (As adopted by EU)
Council Regulation (EEC) No 2377/90 (repealed)Show full title
Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)
You are here:
What Version
Advanced Features
- Show Geographical Extent(e.g. England, Wales, Scotland and Northern Ireland)
- Show Timeline of Changes
More Resources
Revised version PDFs
- Revised 02/09/20090.44 MB
- Revised 09/08/20090.35 MB
- Revised 06/07/20090.44 MB
- Revised 16/08/20080.35 MB
- Revised 05/05/20080.34 MB
- Revised 20/01/20080.35 MB
- Revised 21/08/20070.33 MB
- Revised 16/05/20070.33 MB
- Revised 12/02/20070.33 MB
- Revised 21/01/20070.34 MB
- Revised 08/04/20060.37 MB
- Revised 19/11/20050.29 MB
- Revised 18/10/20050.29 MB
- Revised 14/09/20050.29 MB
- Revised 11/07/20050.29 MB
- Revised 20/03/20050.29 MB
- Revised 22/02/20050.28 MB
- Revised 28/12/20040.28 MB
- Revised 16/08/20030.27 MB
- Revised 28/06/20030.27 MB
- Revised 11/06/20030.27 MB
- Revised 05/06/20030.27 MB
- Revised 27/05/20030.27 MB
- Revised 17/03/20030.27 MB
- Revised 30/12/20020.27 MB
- Revised 01/12/20020.26 MB
- Revised 27/10/20020.26 MB
- Revised 31/08/20020.26 MB
- Revised 24/07/20020.26 MB
- Revised 19/03/20020.26 MB
- Revised 27/02/20020.25 MB
- Revised 07/01/20020.25 MB
- Revised 26/11/20010.25 MB
- Revised 14/11/20010.25 MB
- Revised 22/10/20010.25 MB
- Revised 29/09/20010.25 MB
- Revised 17/09/20010.25 MB
- Revised 28/08/20010.25 MB
- Revised 27/08/20010.25 MB
- Revised 26/06/20010.25 MB
- Revised 18/06/20010.24 MB
- Revised 28/02/20010.24 MB
- Revised 17/01/20010.23 MB
- Revised 27/12/20000.23 MB
- Revised 20/12/20000.23 MB
- Revised 15/11/20000.23 MB
- Revised 20/08/20000.22 MB
- Revised 19/08/20000.22 MB
- Revised 21/02/20000.22 MB
- Revised 20/02/20000.21 MB
- Revised 07/02/20000.20 MB
- Revised 11/01/20000.19 MB
- Revised 10/01/20000.19 MB
- Revised 10/11/19990.19 MB
- Revised 09/11/19990.18 MB
- Revised 11/07/19990.17 MB
- Revised 05/07/19990.16 MB
- Revised 26/06/19990.16 MB
- Revised 16/06/19990.16 MB
- Revised 08/05/19990.15 MB
- Revised 18/05/19920.06 MB
Legislation originating from the EU
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
This item of legislation originated from the EU
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Changes over time for: Division 1.
Version Superseded: 18/10/2005
Alternative versions:
Status:
Point in time view as at 20/03/2005.
Changes to legislation:
There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), Division
1.
.
Changes to Legislation
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
[F11. Anti-infectious agents U.K.
1.1. Chemotheurapeutics U.K.
1.1.2. Benzenesulphonamides U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Clorsulon | Clorsulon | Bovine | 50 μg/kg | Muscle | Provisional MRLs expire on 1 January 2000 |
| 150 μg/kg | Liver | ||||
| 400 μg/kg | Kidney |
1.2. Antibiotics U.K.
1.2.1. Beta-lactamase inhibitors U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Clavulanic acid | Clavulanic acid | Bovine, ovine | 200 μg/kg | Milk | [F2Provisional MRLs expire on 1 July 2001] |
| Bovine, ovine, porcine | 200 μg/kg | Muscle | |||
| 200 μg/kg | Fat | ||||
| 200 μg/kg | Liver | ||||
| 200 μg/kg | Kidney |
Textual Amendments
F2 Substituted by Commission Regulation (EC) No 1943/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
1.2.2. Macrolides U.K.
| a [F3Provisional MRLs expire on 1 July 2006 . | |||||
| b Not for use in animals from which eggs are produced for human consumption.] | |||||
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| [F4Acetylisovaleryltylosin | Sum of acetylisovaleryltylosin and 3-O-acetyltylosin | Porcine | 100 μg/kg | Muscle | Provisional MRLs expire on 1.7.2001 |
| 100 μg/kg | Skin and fat | ||||
| 100 μg/kg | Liver | ||||
| 100 μg/kg | Kidney] | ||||
| [F3Acetylisovaleryltylosin a | Sum of acetyl-isovaleryltylosin and 3-O-acetyltylosin | Poultry b | 50 μg/kg | Skin and fat | |
| 50 μg/kg | Liver | ] | |||
| Erythromycin | MRLs apply to all microbiological active residues expressed as erythromycin equivalent | Bovine, ovine | 40 μg/kg | Milk | Provisional MRLs expire on 1 June 2000 |
| Bovine, ovine, porcine, poultry | 400 μg/kg | Muscle | |||
| 400 μg/kg | Fat | ||||
| 400 μg/kg | Liver | ||||
| 400 μg/kg | Kidney | ||||
| Poultry | 200 μg/kg | Eggs | |||
| Josamycin | Josamycin | Chicken | 200 μg/kg | Muscle | [F5Provisional MRLs expire on 1.7.2002] |
| 200 μg/kg | Fat | ||||
| 200 μg/kg | Liver | ||||
| 400 μg/kg | Kidney | ||||
| 200 μg/kg | Eggs | ||||
| [F6 | Sum of the microbiologically active metabolites, expressed as josamycin | Porcine | 200 μg/kg | Muscle | Provisional MRLs expire on 1.7.2002 |
| 200 μg/kg | Skin and fat | ||||
| 200 μg/kg | Liver | ||||
| 400 μg/kg | Kidney] | ||||
| [F7Tilmicosin | Tilmicosin | Bovine | 40 μg/kg | Milk | Provisional MRLs expire on 1.1.2001] |
| [F8Tulathromycin | (2R,3S,4R,5R,8R,10R,11R,12S, 13S,14R)-2- ethyl-3,4,10,13-tetrahydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa- 6-azacyclopent-decan-15-one expressed as tulathromycin equivalents | Bovine | 100 μg/kg | Fat | Provisional MRLs expire on 1 July 2004 ; not for use in animals from which milk is produced for human consumption |
| 3 000 μg/kg | Liver | ||||
| 3 000 μg/kg | Kidney | ||||
| Porcine | 100 μg/kg | Skin and fat | Provisional MRLs expire on 1 July 2004 | ||
| 3 000 μg/kg | Liver | ||||
| 3 000 μg/kg | Kidney] | ||||
Textual Amendments
F3 Inserted by Commission Regulation (EC) No 75/2005 of 18 January 2005 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards moxidectin, linear alkyl benzene sulphonic acids with alkyl chain lengths ranging from C9 to C13, containing less than 2,5 % of chains longer than C13 and Acetylisovaleryltylosin (Text with EEA relevance).
F4 Inserted by Commission Regulation (EC) No 1286/2000 of 19 June 2000 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F5 Substituted by Commission Regulation (EC) No 2338/2000 of 20 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F6 Inserted by Commission Regulation (EC) No 953/1999 of 5 May 1999 amending Annexes II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F7 Inserted by Commission Regulation (EC) No 2593/1999 of 8 December 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F8 Inserted by Commission Regulation (EC) No 1937/2002 of 30 October 2002 amending Annexes II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F91.2.4. Cephalosporins U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Cefacetrile | Cefacetrile | Bovine | 125 μg/kg | Milk | [F10Provisional MRLs expire on 1.1.2002] For intrammamary use only |
| [F11Cefalonium | Cefalonium | Bovine | 10 μg/kg | Milk | [F12Provisional MRLs expire on 1.1.2003] ] |
| [F13Cefoperazone | Cefoperazone | Bovine | 50 μg/kg | Milk | Provisional MRLs expire on 1 January 2001] |
| [F14Cefquinome | Cefquinome | Porcine | 50 μg/kg | Muscle | Provisional MRLs expire on 1.1.2000 |
| 50 μg/kg | Skin + fat | ||||
| 100 μg/kg | Liver | ||||
| 200 μg/kg | Kidney] | ||||
| Cephapirin | Sum of cephapirin and desacetylcephapirin | Bovine | 50 μg/kg | Muscle | Provisional MRLs expire on 1.1.2001 |
| 50 μg/kg | Fat | ||||
| 50 μg/kg | Liver | ||||
| 100 μg/kg | Kidney | ||||
| 10 μg/kg | Milk] |
Textual Amendments
F10 Substituted by Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F11 Inserted by Commission Regulation (EC) No 2728/1999 of 20 December 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F12 Substituted by Commission Regulation (EC) No 1322/2001 of 29 June 2001 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F13 Inserted by Commission Regulation (EC) No 1943/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Textual Amendments
F9 Inserted by Commission Regulation (EC) No 804/1999 of 16 April 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
1.2.5. Aminoglycosides U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Aminosidine | Aminosidine | Bovine, porcine, rabbits, chicken | 500 μg/kg | Muscle | Provisional MRLs expire on 1 July 2000 |
| 1 500 μg/kg | Liver | ||||
| 1 500 μg/kg | Kidney | ||||
| Apramycin | Apramycin | Bovine | 1 000 μg/kg | Muscle | Provisional MRLs expire on 1 July 1999 |
| For use in non-lactating cattle only | 1 000 μg/kg | Fat | |||
| 10 000 μg/kg | Liver | ||||
| 20 000 μg/kg | Kidney | ||||
| Porcine | 1 000 μg/kg | Muscle | |||
| 1 000 μg/kg | Skin and fat | ||||
| 1 000 μg/kg | Liver | ||||
| 5 000 μg/kg | Kidney | ||||
| [F15Dihydrostreptomycin | Dihydrostreptomycin | Bovine, ovine | 500 μg/kg | Muscle | Provisional MRLs expire on 1.6.2002 |
| 500 μg/kg | Fat | ||||
| 500 μg/kg | Liver | ||||
| 1 000 μg/kg | Kidney | ||||
| 200 μg/kg | Milk | ||||
| Porcine | 500 μg/kg | Muscle | |||
| 500 μg/kg | Skin and fat | ||||
| 500 μg/kg | Liver | ||||
| 1 000 μg/kg | Kidney | ||||
| Gentamicin | Gentamicin | Bovine | 100 μg/kg | Milk | Provisional MRLs expire on 1.6.2002 |
| Bovine, porcine | 50 μg/kg | Muscle | |||
| 50 μg/kg | Fat | ||||
| 200 μg/kg | Liver | ||||
| 750 μg/kg | Kidney] | ||||
| [F16Kanamycin | Kanamycin | Rabbits | 100 μg/kg | Muscle | [F17Provisional MRLs expire on 1.1.2004] |
| 100 μg/kg | Fat | ||||
| 600 μg/kg | Liver | ||||
| 2 500 μg/kg | Kidney | ||||
| Bovine, ovine | 100 μg/kg | Muscle | |||
| 100 μg/kg | Fat | ||||
| 600 μg/kg | Liver | ||||
| 2 500 μg/kg | Kidney | ||||
| 150 μg/kg | Milk | ||||
| Porcine, chicken | 100 μg/kg | Muscle | |||
| 100 μg/kg | Skin + fat | ||||
| 600 μg/kg | Liver | ||||
| 2 500 μg/kg | Kidney] | ||||
| [F15Neomycin (including framycetin) | Neomycin B | Bovine, porcine, chicken | 500 μg/kg | Muscle | Provisional MRLs expire on 1.6.2002 |
| 500 μg/kg | Fat | ||||
| 500 μg/kg | Liver | ||||
| 5 000 μg/kg | Kidney | ||||
| Bovine | 500 μg/kg | Milk | |||
| Chicken | 500 μg/kg | Eggs] | |||
| Spectinomycin | Spectinomycin | Bovine | 200 μg/kg | Milk | Provisional MRLs expire on 1 July 2000 |
| Bovine, porcine, poultry | 300 μg/kg | Muscle | |||
| 500 μg/kg | Fat | ||||
| 2 000 μg/kg | Liver | ||||
| 5 000 μg/kg | Kidney | ||||
| [F11 | Ovine Not for use in animals from which milk is produced for human consumption | 300 μg/kg | Muscle | Provisional MRLs expire on 1.1.2002 | |
| 500 μg/kg | Fat | ||||
| 2 000 μg/kg | Liver | ||||
| 5 000 μg/kg | Kidney | ||||
| Chicken | 200 μg/kg | Eggs] | |||
| [F15Streptomycin | Streptomycin | Bovine, ovine | 500 μg/kg | Muscle | Provisional MRLs expire on 1.6.2002 |
| 500 μg/kg | Fat | ||||
| 500 μg/kg | Liver | ||||
| 1 000 μg/kg | Kidney | ||||
| 200 μg/kg | Milk | ||||
| Porcine | 500 μg/kg | Muscle | |||
| 500 μg/kg | Skin and fat | ||||
| 500 μg/kg | Liver | ||||
| 1 000 μg/kg | Kidney] |
Textual Amendments
F15 Substituted by Commission Regulation (EC) No 1960/2000 of 15 September 2000 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F16 Inserted by Commission Regulation (EC) No 1931/1999 of 9 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F17 Substituted by Commission Regulation (EC) No 2162/2001 of 7 November 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
1.2.6. Quinolones U.K.
| a [F18Provisional MRLs expire 1 January 2006 . | |||||
| b Not for use in animals from which milk is produced for human consumption.] | |||||
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| [F6Danofloxacin | Danofloxacin | Porcine | 100 μg/kg | Muscle | Provisional MRLs expire on 1.1.2000 |
| 50 μg/kg | Skin and fat | ||||
| 200 μg/kg | Liver | ||||
| 200 μg/kg | Kidney] | ||||
| Decoquinate | Decoquinate | Bovine, ovine | 500 μg/kg | Muscle | Provisional MRLs expire on 1 July 2000 |
| 500 μg/kg | Fat | ||||
| 500 μg/kg | Liver | ||||
| 500 μg/kg | Kidney | ||||
| [F19Difloxacin | Difloxacin | Bovine Not for use in animals from which milk is produced for human consumption | 400 μg/kg | Muscle | Provisional MRLs expire on 1.1.2001 |
| 100 μg/kg | Fat | ||||
| 1 400 μg/kg | Liver | ||||
| 800 μg/kg | Kidney | ||||
| Porcine | 400 μg/kg | Muscle | |||
| 100 μg/kg | Skin and fat | ||||
| 800 μg/kg | Liver | ||||
| 800 μg/kg | Kidney] | ||||
| Enrofloxacin | Sum of enrofloxacin and ciprofloxacin | Ovine | 100 μg/kg | Muscle | Provisional MRLs expire on 1 July 1999 |
| 100 μg/kg | Fat | ||||
| 300 μg/kg | Liver | ||||
| 200 μg/kg | Kidney | ||||
| Flumequine | Flumequine | Bovine, ovine, porcine, chicken | 50 μg/kg | Muscle | Provisional MRLs expire on 1 January 2000 |
| 50 μg/kg | Fat or skin and fat | ||||
| 100 μg/kg | Liver | ||||
| 300 μg/kg | Kidney | ||||
| Salmonidae | 150 μg/kg | Muscle and skin | |||
| Marbofloxacin | Marbofloxacin | Bovine | 150 μg/kg | Muscle | Provisional MRLs expire on 1 July 2000 |
| 50 μg/kg | Fat | ||||
| 150 μg/kg | Liver | ||||
| 150 μg/kg | Kidney | ||||
| 75 μg/kg | Milk | ||||
| Porcine | 150 μg/kg | Muscle | |||
| 50 μg/kg | Skin and fat | ||||
| 150 μg/kg | Liver | ||||
| 150 μg/kg | Kidney | ||||
| [F9 [F20Oxolinic acid a | Oxolinic acid | Bovine b | 100 µg/kg | Muscle | |
| 50 µg/kg | Fat | ||||
| 150 µg/kg | Liver | ||||
| 150 µg/kg | Kidney] | ||||
| Porcine | 100 μg/kg | Muscle | |||
| 50 μg/kg | Skin + fat | ||||
| 150 μg/kg | Liver | ||||
| 150 μg/kg | Kidney | ||||
| Chicken | 100 μg/kg | Muscle | |||
| 50 μg/kg | Skin + fat | ||||
| 150 μg/kg | Liver | ||||
| 150 μg/kg | Kidney | ||||
| 50 μg/kg | Eggs | ||||
| Fin fish | 300 μg/kg | Muscle and skin in natural proportions] | |||
Textual Amendments
F18 Inserted by Commission Regulation (EC) No 546/2004 of 24 March 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F19 Inserted by Commission Regulation (EC) No 997/1999 of 11 May 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F20 Substituted by Commission Regulation (EC) No 546/2004 of 24 March 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
1.2.9. Polymyxins U.K.
| Phamarcologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Colistin | Colistin | Bovine, ovine | 50 μg/kg | Milk | [F5Provisional MRLs expire on 1.7.2002] |
| Bovine, ovine, porcine, chicken, rabbits | 150 μg/kg | Muscle | |||
| 150 μg/kg | Fat | ||||
| 150 μg/kg | Liver | ||||
| 200 μg/kg | Kidney | ||||
| Chicken | 300 μg/kg | Eggs |
1.2.10. Penicillins U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| [F9Nafcillin | Nafcillin | Bovine | 300 μg/kg | Muscle | Provisional MRLs expire on 1.1.2001 |
| 300 μg/kg | Fat | ||||
| 300 μg/kg | Liver | ||||
| 300 μg/kg | Kidney | ||||
| 30 μg/kg | Milk] | ||||
| Penethamate | Benzylpenicillin | Ovine | 50 μg/kg | Muscle | Provisional MRLs expire on 1 January 2000 |
| 50 μg/kg | Fat | ||||
| 50 μg/kg | Liver | ||||
| 50 μg/kg | Kidney | ||||
| 4 μg/kg | Milk | ||||
| Porcine | 50 μg/kg | Muscle | |||
| 50 μg/kg | Fat | ||||
| 50 μg/kg | Liver | ||||
| 50 μg/kg | Kidney |
1.2.11. Florfenicol and related compounds U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Florfenicol | Sum of florfenicol and its metabolites measured as florfenicol-amine | Fish | 1 000 μg/kg | Muscle and skin in natural proportions | Provisional MRLs expire on 1 July 2001 |
| [F9Thiamphenicol | Thiamphenicol | Ovine | 50 μg/kg | Muscle | Provisional MRLs expire on 1.1.2001 |
| 50 μg/kg | Fat | ||||
| 50 μg/kg | Liver | ||||
| 50 μg/kg | Kidney | ||||
| Porcine | 50 μg/kg | Muscle | |||
| 50 μg/kg | Skin + fat | ||||
| 50 μg/kg | Liver | ||||
| 50 μg/kg | Kidney | ||||
| Fin fish | 50 μg/kg | Muscle and skin in natural proportions] |
[F61.2.12. Polypeptides U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Bacitracin | Bacitracin | Bovine | 150 μg/kg | Milk | Provisional MRLs expire on 1.7.2001] |
[F91.2.13. Lincosamides U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Lincomycin | Lincomycin | Ovine | 100 μg/kg | Muscle | Provisional MRLs expire on 1.1.2001 |
| 50 μg/kg | Fat | ||||
| 500 μg/kg | Liver | ||||
| 1 500 μg/kg | Kidney | ||||
| 150 μg/kg | Milk | ||||
| Porcine | 100 μg/kg | Muscle | |||
| 50 μg/kg | Skin + fat | ||||
| 500 μg/kg | Liver | ||||
| 1 500 μg/kg | Kidney | ||||
| Chicken | 100 μg/kg | Muscle | |||
| 50 μg/kg | Skin + fat | ||||
| 500 μg/kg | Liver | ||||
| 1 500 μg/kg | Kidney | ||||
| 50 μg/kg | Eggs | ||||
| [F6Pirlimycin | Pirlimycin | Bovine | 100 μg/kg | Muscle | Provisional MRLs expire on 1.7.2000 |
| 100 μg/kg | Fat | ||||
| 1 000 μg/kg | Liver | ||||
| 400 μg/kg | Kidney | ||||
| 100 μg/kg | Milk] ] |
[F111.2.14. Pleuromutilines U.K.
| Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---|---|---|---|---|
| Tiamulin | Sum of metabolites that may be hydrolysed to 8-a-hydroxymutilin | Turkey | 100 μg/kg | Muscle | Provisional MRLs expire on 1.7.2001 |
| 100 μg/kg | Skin and fat | ||||
| 300 μg/kg | Liver] ] |
Textual Amendments
Options/Help
Print Options
PrintThe Whole Regulation
PrintThe Whole Annex
PrintThis Division only
Legislation is available in different versions:
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
See additional information alongside the content
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Opening Options
Different options to open legislation in order to view more content on screen at once
More Resources
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the EU Official Journal
- lists of changes made by and/or affecting this legislation item
- all formats of all associated documents
- correction slips
- links to related legislation and further information resources
Timeline of Changes
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
More Resources
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the print copy
- correction slips
Click 'View More' or select 'More Resources' tab for additional information including:
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- links to related legislation and further information resources
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.